BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine

Trial Profile

BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Vemurafenib (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms BRIM-3
  • Sponsors Roche
  • Most Recent Events

    • 11 Oct 2016 Results of an exploratory analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM studies presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results (n=809) of a pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM study identifying prognostic subgroups and impact of treatment for post-progression overall survival, presented at the 41st European Society for Medical Oncology Congress
    • 07 Jun 2016 Results (n=1223) of a pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM study presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top